神経保護市場：製品、治療、投与経路、用途、エンドユーザー別-2025～2030年の世界予測

神経保護市場は、2023年に2,909億8,000万米ドルと評価され、2024年には3,117億9,000万米ドルに達すると予測され、CAGR 7.63％で成長し、2030年には4,868億9,000万米ドルに達すると予測されています。

神経保護とは、急性または慢性の神経変性障害に直面しても、神経細胞の構造と機能を維持することを目的とした戦略やメカニズムのことです。神経保護介入の必要性は、世界人口の高齢化に伴うアルツハイマー病、パーキンソン病、脳卒中などの神経変性疾患の発症率の増加から生じています。神経保護の用途は、医薬品、バイオテクノロジー製品、ライフスタイルへの介入に及び、最終用途は病院、研究機関、学術研究所です。市場洞察では、ゲノムと創薬における継続的な研究、個別化医療への関心の高まり、医療における政府資金の増加により、その範囲は拡大していると指摘しています。CRISPRや遺伝子治療などの技術的進歩は重要な成長促進要因です。携帯型診断ツールや予測分析におけるAIの台頭も大きな機会をもたらします。主要影響要因としては、非侵襲的な治療オプションに対する需要や、新規ドラッグデリバリーシステムの急速な発展が挙げられます。しかし、市場は、臨床検査にかかる高コスト、規制上のハードル、神経保護薬の潜在的副作用などの課題に直面しています。さらに、長期的な転帰に関する包括的なデータセットが不足しています。企業にとっては、血液脳関門を通過する低分子薬の開発や、患者層別化のための機械学習アルゴリズムの活用など、革新的な戦略に注力することが貴重な道筋となります。マルチ対象薬や併用療法の研究開発は、治療効果を大幅に高める可能性があります。バイオテクノロジー企業と学術機関との革新的な共同研究は、発見を加速させ、競合をもたらす可能性があります。強固なデータ分析と新たな規制枠組みへの準拠を重視することで、市場参入障壁を緩和することができます。神経保護市場は、特に市場開拓の拡大により有望な成長ポテンシャルを示すが、持続的な成長と関連性を維持するためには、既存の制限を慎重に回避し、科学的進歩と市場差別化に戦略的に焦点を当てることが不可欠です。

市場力学：急速に進化する神経保護市場の主要市場洞察を公開

神経保護市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 神経変性疾患の有病率の上昇により、神経保護療法の必要性が高まっている
  • リスク因子を減らすための予防医療とライフスタイルの変化への注目の高まり
  • 神経疾患に対する医療専門家や患者の意識の高まり
• 市場抑制要因
  • 血液脳関門の複雑さによる神経保護剤の送達と効能の制限
• 市場機会
  • 非侵襲的かつ予防的な神経保護戦略の開発のための研究開発投資の増加
  • 個別化された神経保護療法とカスタマイズ可能な治療計画の開発
• 市場課題
  • 神経保護療法の開発と承認を妨げる厳しい規制要件

ポーターのファイブフォース：神経保護市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経保護市場における外部からの影響の把握

外部マクロ環境要因は、神経保護市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：神経保護市場における競合情勢の把握

神経保護市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：神経保護市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経保護市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：神経保護市場における成功への道筋を描く

神経保護市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 神経変性疾患の罹患率の上昇により神経保護療法の必要性が高まっている
    • リスク要因を減らすための予防医療とライフスタイルの変化への注目が高まっている
    • 医療従事者と患者の間で神経疾患に関する意識が高まった
  • 抑制要因
    • 血液脳関門の複雑さが神経保護剤の送達と有効性を制限する
  • 機会
    • 非侵襲的かつ予防的な神経保護戦略の開発に向けた研究開発への投資の増加
    • 個別化された神経保護療法とカスタマイズ可能な治療計画の開発
  • 課題
    • 神経保護療法の開発と承認を妨げる厳しい規制要件
• 市場セグメンテーション分析
  • 製品：神経細胞の生存を維持し、神経変性の進行を防ぐためのアポトーシス阻害剤の利用が増加
  • 用途：健康志向の消費者の間で神経保護の予防に対する嗜好が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 神経保護市場：製品別

• イントロダクション
• アポトーシス阻害剤
• フリー抗炎症剤
• グルタミン酸拮抗薬
• 金属イオンキレート剤
• 神経栄養因子
• ラジカル捕捉剤
• 覚醒剤

第7章 神経保護市場：治療別

• イントロダクション
• アルツハイマー病
• 筋萎縮性側索硬化症
• 脳損傷
• ハンチントン病
• 多発性硬化症
• 神経障害
• 眼の変性
• パーキンソン病

第8章 神経保護市場：投与経路別

• イントロダクション
• 脊髄内
• 静脈内
• 経口
• 経皮

第9章 神経保護市場：用途別

• イントロダクション
• 予防
• 治療

第10章 神経保護市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• クリニック
• 病院
• 製薬・バイオテクノロジー企業

第11章 南北アメリカの神経保護市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の神経保護市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの神経保護市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Boston Scientific、最先端のTCAR技術を求めてSilk Road Medicalを買収し、神経血管ポートフォリオを強化
  • Silk Road Medicalが神経保護を重視したEnroute plus経頸動脈システムを導入
  • Astrocyte Pharmaceuticals、虚血性脳卒中治療AST-004の第2相検査を開始し、前進している
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Abcam PLC by Danaher Corporation
• Anavex Life Sciences corp.
• AstraZeneca PLC
• Astrocyte Pharmaceuticals Inc.
• Bayer AG
• Biogen Inc.
• Bristol Myers Squibb Company（BMS）
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Neuren Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Reata Pharmaceuticals, Inc.
• Sage Therapeutics, Inc.
• Sangamo Therapeutics, Inc.
• Sanofi S.A.
• Sunovion Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. NEUROPROTECTION MARKET RESEARCH PROCESS
• FIGURE 2. NEUROPROTECTION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEUROPROTECTION MARKET DYNAMICS
• TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 53. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. CANADA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. CANADA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. CANADA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. CANADA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 80. CHINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. CHINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 82. CHINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. CHINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. CHINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 85. INDIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. INDIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. INDIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. INDIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. INDIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. JAPAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 97. JAPAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. MALAYSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. MALAYSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. MALAYSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 107. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. SINGAPORE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 112. SINGAPORE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. SINGAPORE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. SINGAPORE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. TAIWAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. TAIWAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. TAIWAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. TAIWAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. THAILAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. THAILAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. THAILAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. THAILAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. VIETNAM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 132. VIETNAM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. VIETNAM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. VIETNAM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. DENMARK NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. DENMARK NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. DENMARK NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. DENMARK NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. EGYPT NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. EGYPT NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. EGYPT NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. EGYPT NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. FINLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 153. FINLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. FINLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. FINLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. FRANCE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. FRANCE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. FRANCE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. FRANCE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. GERMANY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 163. GERMANY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. GERMANY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. GERMANY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. ISRAEL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 168. ISRAEL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. ISRAEL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. ISRAEL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 171. ITALY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. ITALY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 173. ITALY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. ITALY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. ITALY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 178. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. NIGERIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. NIGERIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. NIGERIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. NIGERIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. NORWAY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 188. NORWAY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. NORWAY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. NORWAY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 191. POLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. POLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 193. POLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. POLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. POLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 196. QATAR NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 197. QATAR NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. QATAR NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. QATAR NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. QATAR NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. RUSSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 203. RUSSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. RUSSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. RUSSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 208. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 213. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. SPAIN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 218. SPAIN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SPAIN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. SPAIN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. SWEDEN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 223. SWEDEN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. SWEDEN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. SWEDEN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 227. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 228. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 232. TURKEY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 233. TURKEY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. TURKEY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. TURKEY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 238. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 242. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 243. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 244. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 246. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 247. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023

The Neuroprotection Market was valued at USD 290.98 billion in 2023, expected to reach USD 311.79 billion in 2024, and is projected to grow at a CAGR of 7.63%, to USD 486.89 billion by 2030.

Neuroprotection refers to strategies and mechanisms aimed at preserving the structure and function of neurons in the face of acute or chronic neurodegenerative insults. The necessity of neuroprotective interventions arises from the increasing incidence of neurodegenerative diseases like Alzheimer's, Parkinson's, and stroke due to the aging global population. The application of neuroprotection spans pharmaceuticals, biotechnology products, and lifestyle interventions, with end-use seen in hospitals, research, and academic laboratories. Market insight points to an expanding scope due to ongoing research in genomics and drug discovery, burgeoning interest in personalized medicine, and increased governmental funding in healthcare. Technological advancements, such as CRISPR and gene therapy, are significant growth drivers. The rise of portable diagnostic tools and AI in predictive analytics also presents major opportunities. Key influencing factors include the demand for non-invasive treatment options and the rapid development of novel drug delivery systems. However, the market faces challenges like high costs of clinical trials, regulatory hurdles, and potential side effects of neuroprotective drugs. Additionally, there is a shortage of comprehensive datasets for long-term outcomes. For businesses, a focus on innovative strategies such as developing small-molecule drugs that cross the blood-brain barrier and leveraging machine learning algorithms for patient stratification are valuable pathways. Research and development into multi-target drugs or combination therapies could significantly enhance therapeutic efficacy. Innovative collaborations between biotech firms and academic institutions could accelerate discoveries, providing a competitive edge. Emphasizing robust data analysis and compliance with emerging regulatory frameworks will ease market entry barriers. While the neuroprotection market shows promising growth potential, particularly with expanding therapeutic development, careful navigation around existing limitations and a strategic focus on scientific advancement and market differentiation are essential for sustained growth and relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuroprotection Market

The Neuroprotection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
  • Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
  • Increased awareness among healthcare professionals and patients about neurological conditions
• Market Restraints
  • Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
• Market Opportunities
  • Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
  • Development of personalized neuroprotective therapies and customizable treatment plans
• Market Challenges
  • Stringent regulatory requirements hindering the development and approval of neuroprotective therapies

Porter's Five Forces: A Strategic Tool for Navigating the Neuroprotection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuroprotection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuroprotection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuroprotection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuroprotection Market

A detailed market share analysis in the Neuroprotection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuroprotection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuroprotection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuroprotection Market

A strategic analysis of the Neuroprotection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroprotection Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam PLC by Danaher Corporation, Anavex Life Sciences corp., AstraZeneca PLC, Astrocyte Pharmaceuticals Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Company (BMS)., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Neuren Pharmaceuticals, Novartis AG, Pfizer Inc., Reata Pharmaceuticals, Inc., Sage Therapeutics, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroprotection Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Apoptosis Inhibitors, Free Anti-Inflammatory Agents, Glutamate Antagonists, Metal Ion Chelators, Neurotrophic Factors, Radical Trapping Agents, and Stimulants.
• Based on Treatment, market is studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease, Multiple Sclerosis, Neuropathies, Ocular Degeneration, and Parkinson's Disease.
• Based on Route of Administration, market is studied across Intrathecal, Intravenous, Oral, and Transdermal.
• Based on Application, market is studied across Prevention and Treatment.
• Based on End Users, market is studied across Academic & Research Institutes, Clinics, Hospitals, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
    • 5.1.1.2. Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
    • 5.1.1.3. Increased awareness among healthcare professionals and patients about neurological conditions
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
    • 5.1.3.2. Development of personalized neuroprotective therapies and customizable treatment plans
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements hindering the development and approval of neuroprotective therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Growing utilization of apoptosis inhibitors to maintain neuronal survival and prevent the progression of neurodegeneration
  • 5.2.2. Application: Growing preference for prevention of neuroprotection among health-conscious consumers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neuroprotection Market, by Product

• 6.1. Introduction
• 6.2. Apoptosis Inhibitors
• 6.3. Free Anti-Inflammatory Agents
• 6.4. Glutamate Antagonists
• 6.5. Metal Ion Chelators
• 6.6. Neurotrophic Factors
• 6.7. Radical Trapping Agents
• 6.8. Stimulants

7. Neuroprotection Market, by Treatment

• 7.1. Introduction
• 7.2. Alzheimer's Disease
• 7.3. Amyotrophic Lateral Sclerosis
• 7.4. Brain Injury
• 7.5. Huntington's Disease
• 7.6. Multiple Sclerosis
• 7.7. Neuropathies
• 7.8. Ocular Degeneration
• 7.9. Parkinson's Disease

8. Neuroprotection Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intrathecal
• 8.3. Intravenous
• 8.4. Oral
• 8.5. Transdermal

9. Neuroprotection Market, by Application

• 9.1. Introduction
• 9.2. Prevention
• 9.3. Treatment

10. Neuroprotection Market, by End Users

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Clinics
• 10.4. Hospitals
• 10.5. Pharmaceutical & Biotechnology Companies

11. Americas Neuroprotection Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Neuroprotection Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Neuroprotection Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Boston Scientific to enhance neurovascular portfolio with Silk Road Medical acquisition for cutting-edge TCAR technology
  • 14.3.2. Silk Road Medical's introduction of the Enroute plus transcarotid system emphasizing neuroprotection
  • 14.3.3. Astrocyte Pharmaceuticals moves forward with AST-004 as it enters phase 2 trials for ischemic stroke treatment
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Abcam PLC by Danaher Corporation
• 3. Anavex Life Sciences corp.
• 4. AstraZeneca PLC
• 5. Astrocyte Pharmaceuticals Inc.
• 6. Bayer AG
• 7. Biogen Inc.
• 8. Bristol Myers Squibb Company (BMS).
• 9. Daiichi Sankyo Company, Limited
• 10. Eisai Co., Ltd.
• 11. Eli Lilly and Company
• 12. F. Hoffmann-La Roche Ltd.
• 13. GlaxoSmithKline PLC
• 14. Ionis Pharmaceuticals, Inc.
• 15. Johnson & Johnson Services, Inc.
• 16. Merck & Co., Inc.
• 17. Neuren Pharmaceuticals
• 18. Novartis AG
• 19. Pfizer Inc.
• 20. Reata Pharmaceuticals, Inc.
• 21. Sage Therapeutics, Inc.
• 22. Sangamo Therapeutics, Inc.
• 23. Sanofi S.A.
• 24. Sunovion Pharmaceuticals Inc
• 25. Teva Pharmaceutical Industries Ltd.